The Analysis Of Qinghai Area Of Gestational Trophoblastic Tumor Chemotherapy And Clinical Prognosis

Objective: To investigate the chemotherapy regimens and clinical effects of gestational trophoblastic neoplasia(GTN) patients in Qinghai regions.Methods: Analysis between December 2007 and December 2015 in qinghai university hospital in-patient department of department of gynaecology diagnose and accept standard chemotherapy of sertoli cell tumor, 142 cases of patients with pregnancy, according to the FIGO prognostic scoring system and anatomic staging divided the patients into low-risk groups(< 7), 75 cases of high risk group of 67 cases(7 points) or higher. Grouping: low risk group of 42 cases were defined as 5- FU chemotherapy, 33 cases received MTX chemotherapy is defined as MTX group; High risk group of 34 cases received 5- FU + KSM chemotherapy defined as 5- FU + KSM group, 33 cases received EMA- CO chemotherapy is defined as EMA- CO group. Respectively in two groups were observed apparent side effects as well as the detection index of abnormal, do statistical processing, draw the conclusionResults: Low-risk group the treatment of patients with the MTX group and 5-Fu group high efficient, but the inhibition of MTX on blood more serious, so 5- FU in qinghai region can be used as first-line drug use; High-risk group of two kinds of MDT effectively has the obvious difference, but the EMA – CO group liver damage, kidney damage and blood cells to inhibit the action of the has nothing to do with the treatment purposes such as the high incidence of events, and the cost is relatively high, so in qinghai are used for clinical chemotherapy in patients with high-risk GTN actinomycin to do a line, fluorouracil EMA- CO scheme GTN patients treated as second-line therapyConclusions: Synthesizing the above indicators and statistical comparison, we conclude that both the two drugs achieve satisfactory therapeutic effects and 5-fu can be used as first-line regimens in the treatment of low-risk patients including the experimental and control group. There is difference between the two kinds of combined chemotherapy regimens in the high-risk group. The incidences of side effects such as liver damage, kidney damage and blood cells inhibition are higher in the control group. KSM+FM can be used as the first-line regimen in the clinical treatments, while EMA-CO can be used as second-line regimen.